<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388748</url>
  </required_header>
  <id_info>
    <org_study_id>19-009475</org_study_id>
    <nct_id>NCT04388748</nct_id>
  </id_info>
  <brief_title>Stress Management and Resiliency Training for Depression vs Treatment as Usual in the Treatment of Major Depression</brief_title>
  <official_title>Randomized Controlled Trial of Stress Management and Resiliency Training for Depression (SMART-D) vs Treatment as Usual in the Treatment of Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to find out if a Stress Management and Resiliency Training (SMART-D)
      therapy will help with major depression treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patient health questionnaire depression assessment</measure>
    <time_frame>Baseline, week 1, week 8, 3 months, 6 months</time_frame>
    <description>Measured using the patient health questionnaire (PHQ-9) where total scores are reported on a scale of 1-4 Minimal depression, 5-9 Mild depression, 10-14 Moderate depression, 15-19 Moderately severe depression, 20-27 Severe depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of depression</measure>
    <time_frame>Baseline, week 1, week 8, 3 months, 6 months</time_frame>
    <description>Measured using the 17 item Hamilton Depression Rating scale (HAM-D) where total scores are reported on a scale of 0 - 7 = Normal, 8 - 13 = Mild Depression, 14-18 = Moderate Depression, 19 - 22 = Severe Depression, &gt; 23 = Very Severe Depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in measures of resilience</measure>
    <time_frame>1 week, 8 week, 3 month, 6 month</time_frame>
    <description>Measured using the Connor Davidson Resiliency Scale. Subjects are asked to indicate if they agree with 25 statements on a scale of 0=not true at all, 1=rarely true, 2=sometimes true, 3=often true and 4=true nearly all the time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changed in perceived stress scale</measure>
    <time_frame>1 week, 8 week, 3 month, 6 month</time_frame>
    <description>Measured using Perceived Stress Scale (PSS). Subjects are asked to answer a 10 question about their feelings and thoughts during the last month using a scale of 0 = Never, 1 = Almost Never, 2 = Sometimes, 3 = Fairly Often, 4 = Very Often</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>SMART-D Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will participate in Stress Management and Resiliency Training for Depression (SMART-D) therapy as well as treatment as usual which consists of any ongoing medication or psychotherapy based treatments that are currently in place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment as usual will consist of any ongoing medication or psychotherapy based treatments that are currently in place.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress Management and Resiliency Training for Depression (SMART-D) Therapy</intervention_name>
    <description>4 weekly SMART-D group therapy sessions and 2 telephone based group sessions over 8 weeks</description>
    <arm_group_label>SMART-D Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be enrolled for this study from patients attending the Mayo Clinic
             Depression Center, Mayo Clinic Family Medicine clinics, Behavioral Health and Primary
             Care Clinic at Mayo Clinic Health System, Austin, MN, with a diagnosis of major
             depression, in partial or near remission with PHQ-9 scores â‰¤14

          -  Participants will be required to be between 25 and 80 years old

          -  Able to speak English

          -  Able to provide written informed consent to participate in the study

          -  Participants must have DSM-V diagnostic confirmation of major depressive disorder
             (MDD) (American Psychiatric Association 2013).

          -  Participants will continue taking any prescribed medications from their clinical
             treatment team.

          -  Participants with co-morbid secondary diagnoses of persistent depressive disorder and
             generalized anxiety disorders will be included in the study.

          -  Participants must consent to audio recording of random group sessions which will be
             disclosed at the final study session.

        Exclusion Criteria:

          -  Participants with bipolar disorder, active psychosis, active suicidal ideations, and
             active substance abuse meeting criteria for substance use disorders except nicotine,
             obsessive compulsive disorder, active panic disorder with agoraphobia or other phobic
             disorder, active posttraumatic stress disorder, active severe personality disorders
             will be excluded.

          -  Pregnant women - because of time duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashok Seshadri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Health System in Austin</name>
      <address>
        <city>Austin</city>
        <state>Minnesota</state>
        <zip>55912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ashok Seshadri</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

